XFOR
X4 Pharmaceuticals Inc
Chart
Stats
Earnings
News
Splits
Dividends
Earnings
| Actual EPS |
|---|
| Consensus EPS |
| Estimated EPS |
| Number of Estimates |
| EPS Surprise |
Stats
Summary
x4 pharmaceuticals is developing novel therapeutics designed to improve immune cell trafficking and reverse immune suppression, which is fundamental to treating cancer and certain rare, genetic primary immunodeficiency diseases. our oral, small molecule drug candidates inhibit the binding of chemokine cxcl12 to c-x-c receptor type 4 (cxcr4), a receptor-ligand pair that plays an essential role in normal immune surveillance. we are committed to advancing the fields of cancer immunotherapy and genetic immune disorders through innovation and investment in our proprietary clinical and preclinical pipeline. x4’s most advanced product candidate, x4p-001-rd, is in a phase 2/3 study in patients with whim syndrome, a rare genetic, primary immunodeficiency disease. x4p-001-io is currently under investigation in multiple phase 1/2 studies in refractory clear cell renal cell carcinoma (ccrcc) and melanoma. our third program, x4p-002, is in preclinical development and designed specifically for the t
Market Cap: 161 Million
Primary Exchange: NASDAQ
Website: http://www.x4pharma.com/
Shares Outstanding: 167 Million
Float: 0
Dividend: 0.0 (0.0%)
Beta: 1.8132587599241112
Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Ethical Flags
Longest drawdown: 1038 trading days
From: 2019-03-21 To: 2024-03-07
Lowest Point:
X4 Pharma to fund no-cost genetic testing for rare immune deficiency disorder; shares up 3%
via: SeekingAlpha at 2019-06-12 06:35:20:000
Aimed at providing greater access to faster and earlier diagnosis for people who may have a genetic mutation linked to WHIM syndrome and severe congenital neutropenia, X4 Pharmaceuticals ( XFOR +2.6% ) will partner with Invitae ( NVTA -1.4% ) to offer free-of-charge genetic testin… read more...
X4 Pharma to fund no-cost genetic testing for rare immune deficiency disorder; shares up 3%
via: SeekingAlpha at 2019-06-12 06:35:20:000
Aimed at providing greater access to faster and earlier diagnosis for people who may have a genetic mutation linked to WHIM syndrome and severe congenital neutropenia, X4 Pharmaceuticals ( XFOR +2.6% ) will partner with Invitae ( NVTA -1.4% ) to offer free-of-charge genetic testin… read more...
X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease
via: Business Wire at 2019-06-12 04:30:00:000
Genetic testing to enable improved patient diagnoses and provide valuable disease-specific genetic insights for X4 clinical development of novel therapies X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeu… read more...
X4 Pharmaceuticals and Invitae Announce Partnership to Provide No-Cost Genetic Testing to Patients Suspected of Primary Immunodeficiency Disease
via: Business Wire at 2019-06-12 04:30:00:000
Genetic testing to enable improved patient diagnoses and provide valuable disease-specific genetic insights for X4 clinical development of novel therapies X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a clinical-stage biopharmaceutical company focused on the development of novel therapeu… read more...
| Ex-Date | Payment Date | Record Date | Declared Date | Amount | Flag | Dividend Type | Qualified | Indicated |
|---|
| Ex-Date | Declared Date | Record Date | Payment Date | Ratio | To Factor | For Factor |
|---|